卵巢癌临床试验中尼拉帕尼和他汀类药物的潜在协同效应。

IF 2 Q3 ONCOLOGY

Cancer research communications Pub Date : 2025-01-01 DOI:10.1158/2767-9764.CRC-24-0191

Hailei Zhang, Anna Rutkowska, Antonio González-Martín, Mansoor R Mirza, Bradley J Monk, Ignace Vergote, Bhavana Pothuri, Whitney A Spannuth Graybill, Carsten Goessel, Olena Barbash, Giovanna Bergamini, Bin Feng

{"title":"卵巢癌临床试验中尼拉帕尼和他汀类药物的潜在协同效应。","authors":"Hailei Zhang, Anna Rutkowska, Antonio González-Martín, Mansoor R Mirza, Bradley J Monk, Ignace Vergote, Bhavana Pothuri, Whitney A Spannuth Graybill, Carsten Goessel, Olena Barbash, Giovanna Bergamini, Bin Feng","doi":"10.1158/2767-9764.CRC-24-0191","DOIUrl":null,"url":null,"abstract":"Significance: The presented retrospective analysis suggests, to the best of our knowledge for the first time, a potential significant interaction between statins and niraparib in clinical settings. Nevertheless, further investigations are required to gain a better understanding of the potential clinical benefit.","PeriodicalId":72516,"journal":{"name":"Cancer research communications","volume":" ","pages":"178-186"},"PeriodicalIF":2.0000,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11775730/pdf/","citationCount":"0","resultStr":"{\"title\":\"Potential Synergistic Effect between Niraparib and Statins in Ovarian Cancer Clinical Trials.\",\"authors\":\"Hailei Zhang, Anna Rutkowska, Antonio González-Martín, Mansoor R Mirza, Bradley J Monk, Ignace Vergote, Bhavana Pothuri, Whitney A Spannuth Graybill, Carsten Goessel, Olena Barbash, Giovanna Bergamini, Bin Feng\",\"doi\":\"10.1158/2767-9764.CRC-24-0191\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Significance: The presented retrospective analysis suggests, to the best of our knowledge for the first time, a potential significant interaction between statins and niraparib in clinical settings. Nevertheless, further investigations are required to gain a better understanding of the potential clinical benefit.\",\"PeriodicalId\":72516,\"journal\":{\"name\":\"Cancer research communications\",\"volume\":\" \",\"pages\":\"178-186\"},\"PeriodicalIF\":2.0000,\"publicationDate\":\"2025-01-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11775730/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Cancer research communications\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1158/2767-9764.CRC-24-0191\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"ONCOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cancer research communications","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1158/2767-9764.CRC-24-0191","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

摘要

本研究探讨了聚腺苷5′-二磷酸[ADP]-核糖)聚合酶（PARP）抑制剂尼拉帕尼（Zejula®）与伴用药他汀类药物之间的潜在临床协同作用，探讨了它们对卵巢癌患者无进展生存期（PFS）的联合影响。我们回顾性分析了尼拉帕尼在卵巢癌中的注册临床试验，以调查尼拉帕尼和他汀类药物之间潜在的相互作用。在PRIMA试验中，与安慰剂组相比，接受尼拉帕尼的患者表现出PFS的改善(风险比=0.62；P

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Potential Synergistic Effect between Niraparib and Statins in Ovarian Cancer Clinical Trials.

Significance: The presented retrospective analysis suggests, to the best of our knowledge for the first time, a potential significant interaction between statins and niraparib in clinical settings. Nevertheless, further investigations are required to gain a better understanding of the potential clinical benefit.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Cancer research communications

自引率

0.00%

发文量